

2024 Raleigh Campus Antibiogram Outpatient

GRAM POSITIVE										
Antibiogram 2024 Raleigh Campus Outpatient	* Anaerobic coverage	Enterococcus faecalis	Enterococcus faecium	Staphylococcus epidermidis	Staphylococcus haemolyticus	Staphylococcus lugdunensis	Staphylococcus saprophyticus	Staph aureus (MSSA)	Staph aureus (MRSA)	
Location		OUTPATIENTS								
# of isolates analyzed		1002	32	390	39	64	321	677	389	
		% Susceptible								
Ampicillin	*	100%	28%							
Ceftaroline								100%	100%	
Clindamycin	*			71%	54%	92%	75%	78%	81%	
Daptomycin		90%						100%	99%	
Erythromycin Base, Enteric	*			47%	28%	91%		66%	16%	
Gentamicin Synergy (high level)		87%	97%							
Levofloxacin		88%	31%							
Linezolid		98%	88%	100%	100%	100%	100%	100%	100%	
Nitrofurantoin		100%	28%	99%	95%	100%	100%	99%	100%	
Oxacillin				52%	38%	100%	46%	100%	0%	
Penicillin G	*	99%	27%	0%	0%	0%	0%	0%	0%	
Streptomycin Synergy (high level)		94%	74%							
Tetracycline/Doxycycline	*			81%	67%	97%	95%	90%	87%	
Trimethoprim-sulfa				69%	77%	98%	99%	94%	84%	
Vancomycin		98%	62%	100%	100%	100%	100%	100%	100%	

<p>This antibiogram has been prepared from SCC SOFT LIS. This antibiogram contains organisms isolated in 2023. Only the first isolate per patient is included in this data. * Denotes activity against anaerobes. Anaerobes are not tested for susceptibility profiles at WakeMed.</p>	<p>17 % of Outpatient MSSA are Clindmycin Inducible Resistant 5% of Outpatient MRSA are Clindamycin Inducible Resistant</p>
---	--

Antibiograms are published annually for WakeMed Raleigh, WakeMed Cary and WakeMed North by the Microbiology Lab and the Antimicrobial Stewardship Program. 919-350-8075

**WakeMed Health and Hospitals
Raleigh, NC**